Sab Biotherapeutics(NASDAQ) SABS

SAB Biotherapeutics makes medicines to help people with immune disorders. It uses cattle to produce human antibodies for treatments. The company focuses on stopping diseases like type 1 diabetes.

Fighting Diabetes with New Science

• SAB-142: Lead immunotherapy candidate designed to delay or prevent stage 3 type 1 diabetes by stopping immune cells from attacking the pancreas.
• Tc-Bovine Platform: Proprietary technology using genetically engineered cattle to produce human-targeted antibodies without needing human plasma donors.
• Immunology Pipeline: Research programs aimed at treating other conditions like lupus and rheumatoid arthritis where the immune system attacks the body.

Moving Toward Late-Stage Trials

• Completed a $175 million Series B financing in July 2025 to support ongoing operations.
• Raised $88.7 million in net proceeds through a public offering in March 2026 for clinical studies.
• Began constructing a second farm facility in South Dakota during Q2 2026 to increase production capacity.
• Initiated the SAFEGUARD Phase 2b clinical trial for the lead product candidate in Q3 2025.
• Received a grant from Breakthrough T1D in July 2026 to co-fund a Phase 3 study.

What Makes the Platform Different?

The company produces specialized human antibodies using a platform that does not require human donors. This approach creates complex treatments that are difficult for competitors to copy through standard biosimilar pathways.

The Financial Scorecard

• Net loss was $22.5 million for the three months ended June 30, 2026, up 122.4% year over year.
• Research and development expenses rose to $16.2 million in Q2 2026, up 131.1% year over year.
• Market capitalization reached $311 million in Q2 2026, up 1,801.4% from the previous year.
• Accumulated deficit totaled $152.3 million as of June 30, 2026.
• General and administrative costs increased 163.4% to $7.2 million in the three months ended June 30, 2026.

Bottom Line

SAB Biotherapeutics has evolved from an early-stage researcher into a clinical-stage firm testing a lead diabetes treatment. The company is expanding its manufacturing capacity and securing capital to fund its path toward potential commercial use.